Skip to main content
. Author manuscript; available in PMC: 2006 Oct 11.
Published in final edited form as: Clin Cancer Res. 2005 May 15;11(10):3869–3878. doi: 10.1158/1078-0432.CCR-04-2238

Fig. 8.

Fig. 8

T-cell responses to peptideTARP1-14 and TARP14-27 in patients with prostate cancer. PBMCs were isolated from seven prostate cancer patients and were stimulated with peptides as described in Materials and Methods. The peptide-stimulated PBMCs derived from patients 1-7 (A-G) produced lymphokines (IFN-γ and/or GM-CSF), and production of lymphokines by PBMCs was inhibited by adding anti – HLA-DR mAb L243 at 10 μg/mL during culture. Column, triplicate determinations; bars, SD. Columns without bars had SD < 10% the value of the mean. ND, not determined.